Skip to main content
Caplight Logo









Cytovale

Cytovale

Private
South San Francisco, CaliforniaHealthcare & Life Scienceshttps://cytovale.com/

Last Round

Series D

Oct 10, 2024

Est. Valuation

$32.25M

Total Funding Raised

$226.59M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Cytovale is a biotechnology company that develops innovative diagnostic technologies using cell mechanics and machine learning to enable the early detection of sepsis.

Sector

Healthcare & Life Sciences

Verticals

Medical Devices, Biotechnology, Healthcare Analytics

Business Model

B2B

Customer Profile

Usage-Based SaaS, Hardware Sales

AI Layer

Application

Keywords

sepsis diagnosticsIntelliSeprapid diagnostic testemergency department diagnosticshost-response testingmedical AIsepsis screeningin vitro diagnosticIVDclinical decision supportwhite blood cell analysisrazor and blade modelmedtechpoint of care testingPOCT

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Cytovale Comparables

Compare Cytovale with similar companies based on industry and business-model similarity.

Cytovale comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Prenosis
81%
Inflammatix
81%
ASEP Medical Holdings Inc.
78%

Cytovale Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series DOct 10, 2024
Series CNov 15, 2023
GrantFeb 8, 2022
GrantMay 19, 2020
Series B ExtensionOct 30, 2019
Grant
Sep 28, 2019

Key People

Founding team and executive leadership

Mara Macdonald

Co-Founder, Former COO And Advisor

Founding Team

Henry Tse

CTO

Executive Team

Bill Blackledge

Chief Financial Officer

Executive Team

Christopher Slachta

Chief Operating Officer

Executive Team

Cytovale Investors

Notable investors and investment history

Cytovale investors
InvestorRounds
Pactolus VenturesSeries B, Series B Extension
CPP InvestmentsSeries D
Dolby Family VenturesSeed, Series A
IT-Farm CorporationSeries A
Thiel FoundationSeed, Series A
Creative VenturesGrant
Baidu VenturesSeries B, Series B Extension

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 7, 2026

    Eric Khairy appointed as the new Chief Marketing Officer.

  • Mar 1, 2025

    Dave Vort appointed as Chief Commercial Officer.

Cytovale Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Cytovale Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Cytovale's valuation, stock price, and market status.

Firmographic Details

HeadquartersSouth San Francisco, California
Employee Range120
Year Founded2013
Last FundingOct 10, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?